Month: April 2026

BROOKFIELD, NEWS, April 01, 2026 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners will hold its first quarter 2026 conference call and webcast on Wednesday, April 29, 2026, at 9:00 a.m. (ET). Results will be released that morning before 7:00 a.m. (ET) and will be available on our website at https://bip.brookfield.com. Participants can join by conference call or webcast. Conference CallPlease pre-register at: BIP2026Q1ConferenceCall Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.WebcastPlease join and register at: BIP2026Q1WebcastAbout Brookfield Infrastructure Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors...

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago. Presentation DetailsTitle: Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein: Impact on RNS Long Episodes and Clinical Seizures Presenter: William...

SANTA FE, N.M. and TORONTO, April 01, 2026 (GLOBE NEWSWIRE) — The Clean Energy Association of New Mexico (“CLEAN”) and Premier American Uranium (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF) are pleased to announce that PUR will serve as a Silver Sponsor of the inaugural Nuclear in New Mexico: Fueling the U.S. Nuclear Renaissance conference. The conference is taking place April 20th to 22nd, 2026, at the Hyatt Regency Tamaya Resort & Spa, located on the Santa Ana Pueblo just north of Albuquerque, New Mexico. Colin Healey, CEO of Premier American Uranium Inc., commented, “We are proud to support the inaugural Nuclear in New Mexico Conference, particularly as we continue to advance our Cebolleta Project. Following the completion of our robust PEA last year, our 2026 programs are focused on further...

CHICAGO and VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced amendments to its brand licensing agreements with wholly-owned subsidiaries of RYTHM, Inc. (“RYTHM” or “RYM”) (Nasdaq: RYM). Effective April 1, 2026, GTI Core, LLC (“GTI Core”), an indirect wholly-owned subsidiary of the Company, has amended its existing Trademark and Recipe License Agreements with VCP IP Holdings, LLC and MC Brands LLC, both wholly-owned subsidiaries of RYTHM. Under the amended agreements, licensing fees transition from revenue-based fees to recurring fixed fees of $70 million cash per year collectively for the license rights to RYTHM...

ROLLING MEADOWS, Ill., April 01, 2026 (GLOBE NEWSWIRE) — RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”), America’s THC Company, today announced amendments to its existing trademark and recipe license agreements with an indirect wholly-owned subsidiary of Green Thumb Industries Inc. (“Green Thumb”). RYTHM and Green Thumb have amended their existing trademark and recipe license agreements for the use of brand intellectual property which includes RYTHM, incredibles, Beboe, Dogwalkers, Doctor Solomon’s, &Shine, and Good Green. Effective April 1, 2026, Green Thumb will pay RYTHM an aggregate fixed annual cash fee of $70 million, subject to an annual increase equal to two times a Consumer Price Index-based escalator. “These amendments create a framework that strengthens our licensing arrangement with Green Thumb over the long...

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) — NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company’s common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at an exercise price of $3.025 per share. The offering includes participation from...

Company expands on its relationship with Flow Capital. Boston, MA, April 01, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX)(“MiniLuxe” or the “Company”), the pioneer in clean nail care and ethical nail services, is pleased to announce that Flow Capital Corporation (TSXV:FW) (“Flow Capital”), a leading provider of flexible growth capital and alternative debt solutions, has completed a follow-on investment of up to US$1.75M pursuant to its existing term loan with the Company, bringing the total amount available to the Company under the facility to up to US$7.925 million. Under the new tranche of the loan, an initial advance of US$1.35 million was funded to the Company on closing, and the Company is also eligible to receive an additional advance of up to US$400,000, subject to the satisfaction of certain financing milestones,...

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathiesMALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies). “This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative...